Fetoplacental vascular tone is modified by magnesium sulfate in the preeclamptic ex vivo human placental cotyledon - 28/08/11
, Bobby C Howard, MD, Brian T Pierce, MD, Nathan J Hoeldtke, MD, Byron C Calhoun, MD, Peter G Napolitano, MD
Reprint requests: Christine Kovac, MD, Department of Obstetrics/Gynecology, Darnall Army Community Hospital, 36000 Darnall Loop, Ft Hood, TX 76544.Abstract |
Objective |
The purpose of this study was to evaluate fetoplacental vascular tone and response to a vasoconstrictor in placentas of preeclamptic and normotensive pregnancies with and without the presence of magnesium sulfate.
Study design |
Two cotyledons from each placenta were selected from preeclamptic (n=8) and normotensive (n=7) pregnancies. In one cotyledon from each pair, the maternal circuit was perfused with magnesium sulfate. The fetal arteries were injected sequentially with angiotensin II (10−10mol and 10−11.5 mol). Perfusion pressures and response to angiotensin II were compared, with regard to preeclampsia and exposure to magnesium sulfate.
Results |
Perfusion pressure was higher in preeclamptic placentas, compared with normotensive placentas (30.4 mm Hg vs 24.4 mm Hg, P=.02). There was a decrease in perfusion pressure with exposure to magnesium sulfate in preeclamptic placentas (22.5 mm Hg, P<.01), but not in normotensive placentas. Fetoplacental vascular response to angiotensin II was not affected by preeclampsia or magnesium sulfate.
Conclusion |
In placentas from preeclamptic pregnancies there is increased fetoplacental perfusion pressure, which decreases with exposure to sulfate.
Le texte complet de cet article est disponible en PDF.Keywords : Preeclampsia, placental perfusion, fetoplacental blood flow, angiotensin II, magnesium sulfate
Plan
 | Supported by the Department of Clinical Investigations at Madigan Army Medical Center. Presented at the Twenty-Third Annual Meeting of the Society for Maternal-Fetal Medicine, San Francisco, Calif, February 3-8, 2003. The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the United States Army, United States Air Force, or Department of Defense. |
Vol 189 - N° 3
P. 839-842 - septembre 2003 Retour au numéro
Article précédent
- The effects of a cyclo-oxygenase II inhibitor on placental artery production of thromboxane and prostacyclin
- Bobby C Howard, Christine M Kovac, Byron C Calhoun, Nathan J Hoeldtke, Peter G Napolitano
- Differential expression of TcR-CD3 zeta as evidence for altered immunoregulation in preeclamptic versus normotensive women
- Garrett K Lam, Paul W Whitecar, Susan Orton, Kim A Boggess, Douglas D Taylor
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?